List of Inlyta drug patents

Inlyta is owned by Pf Prism Cv.

Inlyta contains Axitinib.

Inlyta has a total of 4 drug patents out of which 0 drug patents have expired.

Inlyta was authorised for market use on 27 January, 2012.

Inlyta is available in tablet;oral dosage forms.

Inlyta can be used as axitinib in combination with avelumab for the first-line treatment of patients with advanced renal cell carcinoma, in combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma.

The generics of Inlyta are possible to be released after 12 January, 2037.

INLYTA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6534524 PF PRISM CV Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
Apr, 2025

(2 years from now)

US8791140 PF PRISM CV Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals
Dec, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10570202 PF PRISM CV Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
Feb, 2035

(11 years from now)

US10869924 PF PRISM CV PD-L1 antagonist combination treatments
Jan, 2037

(13 years from now)

Drugs and Companies using AXITINIB ingredient

Market Authorisation Date: 27 January, 2012

Treatment: In combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma; Axitinib in combination with avelumab for the first-line treatment of patients with advanced renal cell carcinoma

Dosage: TABLET;ORAL

How can I launch a generic of INLYTA before it's patent expiration?
More Information on Dosage

INLYTA family patents

18

United States

7

Japan

7

European Union

4

Spain

4

China

3

Portugal

3

Mexico

3

Taiwan, Province of China

3

Korea, Republic of

3

Canada

3

Slovenia

3

Poland

3

Australia

2

Singapore

2

Russia

2

Brazil

2

New Zealand

2

Hong Kong

2

Cyprus

2

Hungary

2

Israel

2

Denmark

1

Turkey

1

Malaysia

1

IB

1

Philippines

1

Argentina

1

EA

1

South Africa

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in